在阿拉伯联合长国的多发性硬化症疾病修改治疗指南
Anu Jacob1, Ahmed Osman Shatila2, Jihad Inshasi3
1Neurological Institute, Cleveland Clinic, Abu Dhabi, United Arab Emirates; The Walton Centre, Liverpool, United Kingdom.
Multiple sclerosis and related disorders
|June 26, 2024
概括
本指南为阿联提供了实用的多发性硬化症 (MS) 治疗策略,考虑到患者的独特需求. 它为疾病修饰疗法 (DMT) 提供了明确的建议,以优化对各种多发性硬化症患者的护理.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 公共卫生 公共卫生
背景情况:
- 阿拉伯联合长国 (阿联) 成立了国家多发性硬化症 (MS) 协会 (NMSS),以应对MS护理中的特定挑战.
- 阿联MS人口的独特因素包括一个庞大的外籍社区,多样化的医疗保险,以及不同的医生/患者对疾病修饰治疗 (DMT) 的偏好.
研究的目的:
- 为阿联人口制定一个务实和适应性强的MS疾病修饰治疗 (DMT) 准则.
- 确保最合适的DMT可供尽可能多的多发性硬化症 (MS) 患者使用.
主要方法:
- 适应全球卫生系统和监管机构的国际最佳实践和建议.
- 将MS分类为子类别,以建议量身定制的治疗选择.
- 对于数据有限或有争议的领域,纳入了常识方法.
主要成果:
- 建议治疗具有不良预后因素的放射性隔离综合征 (RIS) 和临床隔离综合征 (CIS).
- 将DMT与类似的作用机制或药物类别 (例如ocrelizumab和rituximab) 的疗效和安全性等同.
- 允许早期治疗切换,以获得明显的疾病活动或不依赖复发的进展,并建议在一次高效DMT失败后进行自身造血干细胞移植.
结论:
- 提供了关于切换和停止DMT以及在怀孕,哺乳期和儿科MS期间选择DMT的指导.
- 该指南旨在为阿联多样化的多发性硬化症患者群体提供最佳的DMT选择.
- 随着新数据的出现,计划在未来更新,以确保持续的相关性和有效性.
相关概念视频
01:20Myasthenia Gravis: Overview and Treatment
1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K
01:22Alzheimer's Disease: Treatment
178
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
178
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
156
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
156
01:29Inflammatory Bowel Disease IV: Pharmacological Management
125
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
125